Purpose of this Study
This study looks at different treatments for early breast cancer (DCIS). It has four parts:
- Screening: Doctors do tests to see if you can join.
- Treatment: You’re randomly placed in a group to get either standard medicine or a new treatment.
- Surgery Check: After 3 months, doctors decide if surgery is needed.
- Follow-Up: You’ll get check-ups for up to 5 years, and yearly follow-ups for 10 years.
Treatments may include pills, hormone therapy, or small pellets under the skin. You’ll also have tests like MRIs, mammograms, and blood samples.
Who Can Participate?
Eligibility
Who can join this study:
- Adults with a type of early breast cancer called DCIS that is hormone receptor-positive (HR+).
- People who were already diagnosed with HR+ DCIS, even if it shows tiny signs of spreading.
- People who had a breast MRI within the last 2 months and a mammogram within the last 4 months to check the cancer.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
Doctors are doing a study to see if people with a type of early breast cancer called DCIS can be safely treated with medicine instead of surgery. They want to know if using drug therapy and regular breast scans can help avoid surgery while still keeping patients healthy.
Locations
Duke University Hospital
Duke Raleigh Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
DCIS: RECAST Trial - Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: a breast cancer prevention pilot study
Principal Investigator
Tong
Wang
Protocol Number
PRO00117651
NCT ID
NCT06075953
Phase
II
Enrollment Status
Pending Open to Enrollment